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ABSTRACT The cloning of a cDNA for the human andro-
gen receptor gene has resulted in the availability of cDNA
probes that span various parts of the gene, including the entire
steroid-binding domain and part of the DNA-binding domain,
as well as part of the 5' region of the gene. The radiolabeled
probes were used to screen for androgen receptor mutations on
Southern blots prepared by restriction endonuclease digestion
of genomic DNA from human subjects with complete androgen
insensitivity syndrome (AIS). In this investigation, we consid-
ered only patients presenting complete AIS and with the
androgen receptor (-) form as the most probable subjects to
show a gene deletion. One subject from each of six unrelated
families with the receptor (-) form of-complete AIS and 10
normal subjects (6 females and 4 males) were studied. In the 10
normal subjects and in 5 of the 6 patients, identical DNA
restriction fragment patterns were observed with EcoRI and
BamHI. In one affected individual, a partial deletion of the
androgen receptor gene involving the steroid-binding domain
was detected. Analysis of other members of this family con-
firmed the apparent gene deletion. Our data provide- direct
proof that complete AIS in some families can result from a
deletion of the androgen receptor structural gene. However,
other families do not demonstrate such a deletion, suggesting
that point mutations (or small, undetectable deletions) may also
result in the receptor (-) form ofcomplete AIS, adding further
to the genetic heterogeneity of this syndrome.
Male pseudohermaphroditism in humans is defined as a
condition of incomplete masculinization of the fetal external
genitalia in a karyotypically normal 46,XY individual (1).
Among the multiple genetic disorders that result in male
pseudohermaphroditism are a group of abnormalities of the
androgen target cells, including Sa-reductase deficiency and
androgen insensitivity (2, 3). The androgen insensitivity
syndrome (AIS) is an X chromosome-linked disorder (4, 5)
resulting from impairment of the biological actions of andro-
genic hormones related to defects in the intracellular andro-
gen receptor (6-8). Phenotypic expression is quite variable
ranging from complete female phenotype to male genitalia
with mild hypospadias (9, 10). Recent evidence suggests that
the syndrome includes some rare cases of phenotypically
normal males with infertility (11, 12). The heterogeneity in
phenotypic expression is due to the variety of androgen
receptor defects, some of which are detectable by biochem-
ical methods (13-15).
In the complete form ofAIS, affected subjects present with
completely female external genitalia, but with a short vagina
and absent Mullerian ducts; with normal-size testes located
in the abdominal or inguinal area, but with hypoplastic
Wolffian ducts; with normal female secondary-sex charac-
teristics at puberty, but usually sparse or absent pubic and
body hair (2, 3, 9). In adults, serum testosterone and lutropin
concentrations are at or above the normal adult male range
(16). Determination of androgen receptor binding in cultured
genital skin fibroblasts has demonstrated the genetic heter-
ogeneity ofcomplete AIS, some patients having undetectable
binding, or the so-called receptor (-) form, whereas others
have quantitatively normal binding, termed the receptor (+)
form (15, 17, 18).
Cloning and partial analysis of human cDNA encoding the
androgen receptor gene has been reported (19, 20). Various
fragments of the cDNA have been used in the present study
to probe the genome of six unrelated patients with the
receptor ( -) form ofcomplete AIS. Five patients had normal
restriction fragment patterns with EcoRI and BamHI endo-
nucleases, suggesting a point mutation (or small, undetected
deletion) of their androgen receptor gene. In one subject and
her affected sibling, a partial deletion of the gene was
observed, demonstrating further genetic heterogeneity in
receptor (-), complete AIS. A preliminary report of this
work has been presented. 11
MATERIALS AND METHODS
Experimental Subjects. Informed written consent was ob-
tained from each subject according to Johns Hopkins Insti-
tutional Guidelines for Clinical Investigation. We have stud-
ied 10 normal subjects (6 females and 4 males) and 1 affected
individual from each of six unrelated families with the
receptor (-) form of complete AIS. Several members of one
of the families were also studied. The pedigree of this family
is shown in Fig. 1. The father is deceased and the mother (1-2)
was shown to be heterozygous for the androgen receptor
gene mutation (4). Dizygotic twins, II-3 and II-4, as well as
a sibling, 11-7, are phenotypic females including female
external genitalia and breast development, without clitoral
enlargement or posterior labial fusion. They have only sparse
amounts of pubic and axillary hair. In subjects II-3 and 11-4,
plasma testosterone concentrations were 661 and 637 ng/dl
(normal male = 550 + 150 ng/dl) and serum lutropin levels
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FIG. 1. Pedigree of a family with receptor (-) form of complete
AIS. The father (I-1) is deceased; the mother (1-2) is an obligate
heterozygote of this X-linked trait (solid circle inside open circle);
and the three affected 46,XY subjects (solid symbols) are dizygotic
twins, 11-3 and 11-4, and a sibling, 11-7.
were 36.4 and 57.0 milliinternational units/ml (normal male
= 8.9 + 3.5 milliinternational units/ml), respectively (pa-
tients 3 and 4 of ref. 21). Dihydrotestosterone receptor
binding was absent in skin fibroblasts cultured from subjects
11-3 and II-4 but present at normal levels in a sexually normal
brother (11-5), in two younger sisters (II-8 and II-9), and in
their mother (I-2), an obligate heterozygote (4). Five subjects
from this family, 1-2, II-2, 11-3, II-4, and II-9, are included in
this study.
Hybridization Probes. Two of the hybridization probes for
the androgen receptor, hAR-1 and hAR-2, were derived from
clone ARHFLlH-X obtained from a human foreskin fibro-
blast cDNA library as described by Lubahn et al. (20).
ARHFLlH-X contains a portion of the DNA-binding domain
as determined from nucleotide sequence data. When cloned
into the expression vector pCMV, ARHFLlH-X also syn-
thesizes a protein that binds dihydrotestosterone specifically
and with high affinity. As shown in Fig. 2, hAR-1 is a 718-base
pair (bp) cDNA fragment containing a portion of the DNA-
binding domain at its 5' terminus and extending toward the 3'
steroid-binding domain. hAR-2 is a 490-bp cDNA contiguous
with hAR-1 and contains the extreme 3' coding sequence and
some of the 3' noncoding region. hAR-3 is a 575-bp cDNA
fragment derived from clone gtll ARHEL1 that was isolated
from a human epididymal cDNA library and localized on the
5' side ofthe DNA-binding region ofthe gene and 560 bp from
the putative initiation start site for transcription (20). The
human coagulation factor VIII DNA probe was a 5.4-kilobase
pair (kb) genomic fragment from exon 26 of this gene, kindly
provided by Stylios Antonarakis (Johns Hopkins Univer-
sity). All DNA probes were radiolabeled to a specific activity
of 109 cpm/,tg of DNA with [a-32P]dCTP (New England
Nuclear) by a random-priming method (22).
DNA Restriction Analysis. Genomic DNA was isolated
from peripheral leukocytes as described (23) and modified by
our laboratory (24). For extraction of DNA from skin
fibroblasts, cells from 10 to 16 100-mm culture plates were
trypsinized and removed by repeated pipetting with Tris-
buffered saline (10 mM Tris HCI, pH 7.4/0.9% NaCl). Cells
were collected by centrifugation at 800 x g for 5 min at 4°C.
The cells were resuspended in 10 ml of Tris-buffered saline
and resedimented. The cells were resuspended in 10 ml of a
solution of 50mM Tris HCl (pH 7.8), 0.15 M NaCl, and 5 mM
EDTA, incubated in the presence of proteinase K (1-2 mg)
for 15 min at 650C, and then incubated for an additional 12-
16 hr at 370C with shaking. This solution was extracted three
times with an equal volume (10 ml) of phenol/chloroform, 1:
1 (vol/vol), and twice with chloroform/isoamyl alcohol, 24:
1 (vol/vol). DNA was precipitated from the aqueous phase by
the addition of 5 ml of 7.5 M ammonium acetate and 37.5 ml
of ice-cold ethanol followed by centrifugation at 10,000 x g
for 15 min at 4°C. The supernatant was decanted and the
DNA pellet was washed with 5 ml of 80% (vol/vol) ethanol.
DNA was dissolved in 5 ml of 10 mM Tris HCl (pH 7.4) plus
1 mM EDTA (TE) by shaking at 37°C for 12-16 hr. The
solution was treated with RNase A (100 ,ug/ml) for 30 min at
37°C and reextracted twice with 5 ml of phenol/chloroform,
1:1 (vol/vol), once with chloroform, and once with chloro-
form/isoamyl alcohol, 24:1 (vol/vol). DNA was precipitated
from the aqueous phase by the addition of 0.5 ml of 3 M
sodium acetate and 12.5 ml of ice-cold ethanol followed by
centrifugation at 10,000 x g for 15 min at 4°C. The pellet was
washed with 5 ml of ice-cold 80% (vol/vol) ethanol and
recentrifuged. DNA from leukocytes and skin fibroblasts was
incubated in TE buffer at 37°C with shaking until dissolved
and the concentration of each sample was determined spec-
trophotometrically.
DNA (8-10 jig) was digested for 16-20 hr with various
restriction endonucleases according to the manufacturer's
recommendations for buffer and temperature. DNA frag-
ments were separated by agarose gel electrophoresis [1%
(wt/vol)], transferred in alkaline buffer to GeneScreenPlus
(DuPont/NEN), and neutralized on the membrane. The mem-
brane was prehybridized overnight at 42°C in a solution con-
taining 50% (vol/vol) deionized formamide, 5 x Denhardt's
solution, 5 x SSPE, 1% NaDodSO4, 10% (wt/vol) deXtran
sulfate, heparin (25 units/ml), 0.25 mM ATP, and denatured
salmon sperm DNA (100 ,g/ml). (1 x Denhardt's solution =
0.02% polyvinylpyrrolidone/0.02% Ficoll/0.02% bovine se-
rum albumin; 1x SSPE = 0.18 M NaCl/10 mM sodium
phosphate, pH 7.4/1 mM EDTA.) Hybridization was per-
formed by adding the radiolabeled cDNA probe in the same
prehybridization solution to a final concentration of 106
cpm/ml and incubating at 42°C for 24-48 hr. The membranes
were washed successively in (i) 2 x SSC/0.5% NaDodSO4
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FIG. 2. Diagram of the human androgen receptor cDNA and the three fragments used as radiolabeled hybridization probes on Southern blots
ofgenomic DNA. The human androgen receptor from its 5' initiation site (ATG) to its 3' stop codon is encoded by -2800 nucleotides. In addition,
=500 bp of noncoding sequence extends from the stop codon to the beginning of the poly(A) tail. The positions of the DNA- (stippled bar) and
steroid- (solid bar) binding domains are shown. The three cDNA probes used for hybridization and their respective positions within the cDNA
structure are designated as hAR-1, hAR-2, and hAR-3.
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for three 10-min periods at 250C, and (iii) 0.1 x SSC/l.Oo
NaDodSO4 for four 30-min periods at 68-70'C. (1 x SSC =
0.15 M NaCI/0.015 M sodium citrate, pH 7.0.) The mem-
branes were exposed to Kodak XAR-5 film with intensifying
screens at - 70'C for 3-10 days. Blots to be rehybridized with
a second probe were first incubated three times with boiling
0.1 x SSC/0.5% NaDodSO4 and shaking to remove the
original hybridization probe. To ensure complete removal of
the probe, the blots were then exposed to XAR-5 film for 48
hr before rehybridization as described above.
RESULTS
Genomic DNA was extracted from cultured genital skin
fibroblasts or leukocytes of 10 normal subjects and 6 subjects
with the receptor (-) form of complete AIS. DNA was
digested with the restriction endonuclease EcoRI or BamHI
and analyzed by Southern blotting techniques and by hybrid-
ization with the hAR-1 probe. As shown in Fig. 3 Upper, two
restriction fragments of9.4 kb and 2.4 kb were observed after
EcoRI digestion in 5 subjects (lanes A-E) with complete AIS
and also observed in 10 normal male and female subjects
(data not shown). However, subject II-3 showed only the
9.4-kb fragment, suggesting that part of the androgen recep-
tor gene was missing. Further evidence for a partial deletion
of the androgen receptor gene in subject II-3 was apparent
afterDNA digestion withBamHI (Fig. 3 Lower). In 5 affected
subjects (lanes A-E) and control subjects, the hAR-1 cDNA
probe hybridized to restriction fragments of 7.0, 6.0, 5.4, and
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fragments were absent. As a control, the radiolabeled hAR-1
cDNA probe was removed and the same blots were rehybrid-
ized with a radiolabeled 5.4-kb genomic DNA probe for the
human factor VIII gene. This revealed the presence in all six
affected subjects of the expected restriction fragments for
EcoRI of 5.4 kb and forBamHI of 3.4 kb and 2.1 kb (data not
shown).
Further documentation for a partial androgen receptor
gene deletion was provided by DNA restriction fragment
patterns of subject II-3 and other members of her family (Fig.
1). DNA digested with EcoRI and hybridized with radiola-
beled hAR-1 revealed the presence of two restriction frag-
ments of 9.4 and 2.4 kb in the mother (1-2) and two normal
female siblings, 11-2 and II-9 (Fig. 4 Top), a pattern similar to
that shown for three unrelated controls. Subject 11-3 and her
affected nonidentical twin sibling (11-4) showed no evidence
of a 2.4-kb fragment. Rehybridization of this same DNA blot
with radiolabeled hAR-2 cDNA as probe (Fig. 4 Middle)
identified 1.2- and 0.7-kb restriction fragments in the three
controls, in the mother (1-2), and in the two unaffected female
siblings (II-2 and 11-9). However, the 1.2- and 0.7-kb restric-
tion fragments were absent in 11-3 and II-4. By contrast,
rehybridization of this same DNA blot with radiolabeled
hAR-3 cDNA probe revealed the presence of a restriction
fragment of -23 kb for all subjects tested, including the two
with complete AIS (Fig. 4 Bottom). A control hybridization
with the factor VIII probe confirmed that similar amounts of
DNA were applied to each lane (data not shown). However,
the detection of the heterozygous carriers (e.g., subject 1-2)
Kb-2 I- 2
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FIG. 3. Southern blots of genomic DNA from genital skin
fibroblasts of six unrelated subjects with the receptor (-) form of
complete AIS. DNA (8 ,ug) was digested with EcoRI (Upper) or
BamHI (Lower) and analyzed for hybridization with 32P-labeled
hAR-1 cDNA.
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FIG. 4. Southern blots of DNA from genital skin fibroblasts or
leukocytes of five members of the pedigree shown in Fig. 3 with
complete AIS and of three control subjects (two females, one male).
DNA (10 Jg) was digested with EcoRI and analyzed by hybridization
with 32P-labeled hAR-1 (Top), hAR-2 (Middle), and hAR-3 (Bottom).
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of the androgen receptor gene deletion in this family will
require a more definitive assessment ofgene dosage than that
shown in Fig. 4.
The three androgen receptor cDNAs were used to probe
DNA fragments generated by BamHI digestion in members
of the family with complete AIS and in control subjects (Fig.
5). The radiolabeled hAR-1 cDNA probe hybridized with
restriction fragments of 7.0, 6.0, 5.4, and 4.4 kb in normal
subjects, the mother (1-2), and two unaffected siblings (II-2
and 11-9) (Fig. 5 Top). However, 7.0- and 6.0-kb restriction
fragments were absent in the two affected siblings (II-3 and
II-4). Radiolabeled hAR-2 cDNA hybridized with a single
2.0-kb restriction fragment in DNA from normal subjects, the
mother, and two unaffected siblings, but not from the two
affected subjects (Fig. 5 Middle). Rehybridization of this
DNA blot with radiolabeled hAR-3 cDNA probe showed the
presence of an -27-kb restriction fragment in all of the
subjects examined (Fig. 5 Bottom).
DISCUSSION
Complete unresponsiveness to androgens is known as AIS in
humans and as the testicular feminization mutation in mice
(25, 26) and rats (27, 28). Linkage to the X chromosome was
first suggested in rats by analysis of sex ratios (27, 28),
whereas the testicular feminization mutation in mice was
mapped to a linkage group, including tabby and blotchy, that
occupies the distal half of the murine X chromosome (25, 26).
Migeon et al. (5), by producing a series of testicular femini-
zation mutation mouse-human cell hybrids and testing their
expression of androgen receptor binding activity, demon-
strated that the androgen receptor gene or the gene locus of
a factor controlling androgen receptor gene expression was
located on the human X chromosome between Xpl1 and
Controls
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FIG. 5. Southern blots of DNA from genital skin fibroblasts or
leukocytes of five members of the pedigree shown in Fig. 3 with
complete AIS and of three control subjects (two females, one male).
DNA (10 Ag) was digested with BamHI and analyzed by hybridiza-
tion with 32P-labeled hAR-1 (Top), hAR-2 (Middle), and hAR-3
(Bottom).
Xq13. It has been shown that the androgen receptor struc-
tural gene indeed occupies this X chromosome locus (20).
Studies by Wieacker et al. (29) have also presented evidence
for close linkage between the androgen receptor locus and
DXS1 segment.
The androgen receptor belongs to the subfamily of steroid
hormone receptors within a larger family of chromatin-
binding proteins that are likely to have evolved from a
common ancestral gene (for review, see ref. 30). The steroid
receptor genes contain an amino-terminal region of variable
length with a proposed role in transcriptional activation, a
highly conserved central region rich in cysteine residues
required of the zinc-binding finger structure that binds DNA,
and a carboxyl-terminal region where ligand binding occurs.
The cloning ofcDNAs for the human androgen receptor gene
(19, 20) provides the molecular tools to correlate structure
and function and, specifically, to identify and relate the
natural mutations occurring in AIS to the physiologic prop-
erties of androgen receptors.
In the present work, we elected to study patients with
complete AIS who had undetectable androgen receptors by
ligand binding assays (31), in the expectation that some of
them might present a deletion of the androgen receptor gene.
About 5-10% of mutations found in genetic disorders are due
to gene deletions (32-35). Assuming a 5% frequency, screen-
ing of 14 independent mutations of the androgen receptor
gene should result in greater than a 50% chance of finding a
gene deletion. Our group of patients included one affected
subject from each of six unrelated families. One of them
showed a definite deletion when using two endonucleases,
EcoRI and BamHI. This finding demonstrates further genetic
heterogeneity in AIS; some patients with the complete
receptor (-) form have a deletion of the androgen receptor
gene, whereas others have no detectable deletion when
assessed by identical techniques. In the second group, the
gene may not be expressed because of a point mutation or the
mutant gene may express a receptor protein that is structur-
ally modified so as to be unable to bind the androgen ligand.
Additional DNA restriction analysis was carried out in the
patient with identifiable gene deletion and in members of her
family. The use ofthree cDNA probes that spanned the entire
receptor gene demonstrated that the deletion was partial but
affected the entire steroid-binding domain. This was demon-
strated by the absence of several restriction fragments that
hybridized with hAR-1 cDNA, including the 5' portion of this
domain, by the complete absence of the normal restriction
fragments that hybridized with hAR-2 cDNA, including the 3'
portion of the steroid-binding domain, but by a normal
restriction fragment pattern with the hAR-3 cDNA probe,
including a portion of the 5' amino-terminal domain (Fig. 2)
of the androgen receptor. A dizygotic affected sister, two
unaffected sisters, and the mother confirmed the relation of
AIS and restriction fragments observed with the two endo-
nucleases and the three cDNA probes used in the study.
In summary, we have identified a partial deletion of the
human androgen receptor gene in a subject with complete
AIS. The fact that cultured genital skin fibroblasts from this
subject have undetectable androgen receptor binding activity
is correlated with an apparent deletion in the 3' region of the
gene that encodes the carboxyl terminus of the receptor
protein responsible for androgen binding. Initial findings
from other subjects with the receptor (-) form of complete
AIS suggest that gross deletions within the steroid-binding
domain of the receptor do not account for their target cell
insensitivity and hence these mutations may form a hetero-
geneous group of molecular lesions.
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